{"organizations": [], "uuid": "7169192f4e001afcf3c01c5d792bda5588fbed96", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180416.html", "section_title": "Archive News &amp; Video for Monday, 16 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/shire-ma-servier/shire-to-sell-oncology-business-to-servier-for-2-4-bln-idUSL8N1RT0ZA", "country": "US", "domain_rank": 408, "title": "Shire to sell oncology business to Servier for $2.4 bln", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.038, "site_type": "news", "published": "2018-04-16T14:51:00.000+03:00", "replies_count": 0, "uuid": "7169192f4e001afcf3c01c5d792bda5588fbed96"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/shire-ma-servier/shire-to-sell-oncology-business-to-servier-for-2-4-bln-idUSL8N1RT0ZA", "ord_in_thread": 0, "title": "Shire to sell oncology business to Servier for $2.4 bln", "locations": [], "entities": {"persons": [{"name": "sarah young", "sentiment": "none"}, {"name": "kate holton", "sentiment": "none"}], "locations": [{"name": "shire", "sentiment": "none"}, {"name": "london", "sentiment": "none"}, {"name": "japan", "sentiment": "none"}], "organizations": [{"name": "shire", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "servier", "sentiment": "negative"}, {"name": "takeda pharmaceutical", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "LONDON, April 16 (Reuters) - Shire, the London-listed pharmaceutical company which specialises in rare diseases, said on Monday it was selling its oncology business to French drug maker Servier for $2.4 billion.\nShire, which is a possible bid target for Japanâ€™s largest drugmaker Takeda Pharmaceutical, said it would consider returning the proceeds of the sale to shareholders through a buyback. (Reporting by Sarah Young; editing by Kate Holton)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-16T14:51:00.000+03:00", "crawled": "2018-04-17T12:28:27.011+03:00", "highlightTitle": ""}